Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doriano Fabbro

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
British Journal of Pharmacology|December 10, 2015
The Concise Guide to PHARMACOLOGY 2015/16: OverviewStephen Ph Alexander, Eamonn Kelly, Neil Marrion, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein TargetsStephen P H Alexander, Eamonn Kelly, Alistair Mathie, et al.
Cancer Cell|February 16, 2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblEllen Weisberg, Paul W Manley, Werner Breitenstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen, Daniel J Deangelo, Jeffery L Kutok, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Cancer Cell|June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools, Elizabeth H Stover, Christina L Boulton, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
British Journal of Pharmacology|December 10, 2015
The Concise Guide to PHARMACOLOGY 2015/16: OverviewStephen Ph Alexander, Eamonn Kelly, Neil Marrion, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein TargetsStephen P H Alexander, Eamonn Kelly, Alistair Mathie, et al.
Cancer Cell|February 16, 2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblEllen Weisberg, Paul W Manley, Werner Breitenstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen, Daniel J Deangelo, Jeffery L Kutok, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Cancer Cell|June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools, Elizabeth H Stover, Christina L Boulton, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Pageof 13